Outcomes from the REACH registry for Australian general practice patients with or at high risk of atherothrombosis

Medical Journal of Australia

Volumn 196, Issue 3, 2012, Pages 193-197

  Reid, Christopher M ^a   Ademi, Zanfina ^a,b   Nelson, Mark R ^c   Connor, Greg ^d   Chew, Derek P ^e   Shiel, Louise ^a   Smeath, Ana ^f   de Looze, Fred ^g   Steg, Ph Gabriel ^h   Bhatt, Deepak L ⁱ   Lie, Danny ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d Cardiovascular Diagnostic Services   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f Sanofi Aventis   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h Bichat Public Hospital ^*  (France)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; AUSTRALIAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; ETHNIC GROUP; FEMALE; GENERAL PRACTITIONER; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; REGISTER; STROKE;

AGED; ATHEROSCLEROSIS; AUSTRALIA; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; FEMALE; GENERAL PRACTICE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; OBESITY; OVERWEIGHT; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; STROKE; THROMBOSIS;

EID: 84857852640     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja11.10731     Document Type: Article

References (28)

1. Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts 2004. Canberra: AIHW and Heart Foundation of Australia, 2004. (AIHW Cat. No. CVD 27; Cardiovascular Series No. 22). http:// www.aihw.gov.au/publication-detail/?id= 644twofour67598 (accessed Jan 2012).
2. Australian Institute of Health and Welfare. Australia's Health 2008. Canberra: AIHW, 2008. http://www.aihw.gov.au/publication-detail/?id=6442468102 (accessed Jan 2012).
3. Bhatt D, Eagle K, Ohman M, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304: 1350-1357.
4. Ademi Z, Walls HL, Peeters A, et al. Economic implications of obesity among people with atherothrombotic disease. Int J Obes (Lond) 2010; 34: 1284-1292.
5. Shaper A, Pocock S, Phillips A, Walker M. Identifying men at high risk of heart attacks: strategy for use in general practice. BMJ 1986; 293: 474-479.
6. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008; 118: 576-585.
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
9. Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
10. Jones DW, Peterson ED, Bonow RO, et al. Partnering to reduce risks and improve cardiovascular outcomes: American Heart Association initiatives in action for consumers and patients. Circulation 2009; 119: 340-350.
11. Kumanyika SK, Obarzanek E, Stettler N, et al. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance. A scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (Formerly the Expert Panel on Population and Prevention Science). Circulation 2008 July 22, 2008; 118: 428-464.
12. Lancefield T, Clark D, Andrianopoulos N, et al. Is there an obesity paradox after percutaneous coronary intervention (PCI) in the contemporary era? Findings from a large multicentre Australian coronary angioplasty registry. JACC 2010; 3: 660-668.
13. Reid C, Nelson MR, Shiel L, et al. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ 2008; 17: 114-118.
14. Charles J, Britt H, Ng A. Management of cardiovascular conditions in Australian general practice. Aust Fam Physician 2005; 34: 410-411.
15. Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006; 151: 786. e1-10.
16. Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-1206.
17. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
18. Ademi Z, Liew D, Chew D, et al. Drug treatment and cost of cardiovascular disease in Australia. Cardiovasc Ther 2009; 27: 164-172.
19. Ademi Z, Liew D, Hollingsworth B, et al. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry. Am J Cardiovasc Drugs 2010; 10: 85-94.
20. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
21. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005; 165: 55-61.
22. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120: 863-870.
23. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and longterm outcomes after percutaneous coronary intervention: the obesity paradox? Am J Cardiol 2002; 39: 578-584.
24. Zimmet P, Cohen M. The diabetes epidemic in Australia: prevalence, patterns and the public health. Med J Aust 1995; 163: 116-117.
25. Carter JN, Bartley PC. The diabetes epidemic in Australia: prevalence, patterns and the public health. Med J Aust 1996; 164: 51.
26. Zimmet PZ, James WPT. The unstoppable Australian obesity and diabetes juggernaut. What should politicians do? Med J Aust 2006; 185: 187-188.
27. Ohman E, Bhatt D, Wilson P, et al; REACH Registry Investigators. The REACH Registry: an international, prospective, observational investigation in subjects at risk of atherothrombotic events-study design. Am Heart J 2006; 151: 786.
28. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.